These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
991 related items for PubMed ID: 22193059
1. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ). Odkhuu E, Koide N, Haque A, Tsolmongyn B, Naiki Y, Hashimoto S, Komatsu T, Yoshida T, Yokochi T. Immunol Lett; 2012 Feb 29; 142(1-2):34-40. PubMed ID: 22193059 [Abstract] [Full Text] [Related]
2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways. Wu X, Li Z, Yang Z, Zheng C, Jing J, Chen Y, Ye X, Lian X, Qiu W, Yang F, Tang J, Xiao J, Liu M, Luo J. J Bone Miner Res; 2012 Jun 29; 27(6):1298-1308. PubMed ID: 22337253 [Abstract] [Full Text] [Related]
3. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB. Koide N, Kondo Y, Odkhuu E, Ulziisaikhan J, Ukaji T, Yokochi T, Umezawa K. Immunol Lett; 2014 Sep 29; 161(1):31-7. PubMed ID: 24792671 [Abstract] [Full Text] [Related]
4. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T. Bone; 2007 Oct 29; 41(4):592-602. PubMed ID: 17627913 [Abstract] [Full Text] [Related]
5. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K. J Bone Miner Res; 2005 Apr 29; 20(4):653-62. PubMed ID: 15765185 [Abstract] [Full Text] [Related]
7. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH. Mol Pharmacol; 2010 Jan 29; 77(1):17-25. PubMed ID: 19828731 [Abstract] [Full Text] [Related]
8. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos. He L, Lee J, Jang JH, Lee SH, Nan MH, Oh BC, Lee SG, Kim HH, Soung NK, Ahn JS, Kim BY. Bone; 2012 Jun 29; 50(6):1207-13. PubMed ID: 22484180 [Abstract] [Full Text] [Related]
17. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M. J Bone Miner Res; 2011 Mar 29; 26(3):644-56. PubMed ID: 20814972 [Abstract] [Full Text] [Related]
18. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M. Life Sci; 2007 Mar 13; 80(14):1311-8. PubMed ID: 17306833 [Abstract] [Full Text] [Related]
20. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. Yagi M, Ninomiya K, Fujita N, Suzuki T, Iwasaki R, Morita K, Hosogane N, Matsuo K, Toyama Y, Suda T, Miyamoto T. J Bone Miner Res; 2007 Jul 13; 22(7):992-1001. PubMed ID: 17402846 [Abstract] [Full Text] [Related] Page: [Next] [New Search]